Heron Therapeutics (HRTX) 주식 개요
헤론 테라퓨틱스는 상업화 단계의 생명공학 회사로, 의료 서비스를 개선하는 치료제를 개발 및 상용화하는 데 주력하고 있습니다. 자세히 보기
HRTX Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Heron Therapeutics, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$0.43 |
| 52주 최고가 | US$2.28 |
| 52주 최저가 | US$0.38 |
| 베타 | 1.65 |
| 1개월 변동 | -0.40% |
| 3개월 변동 | -48.83% |
| 1년 변동 | -80.65% |
| 3년 변동 | -67.50% |
| 5년 변동 | -96.84% |
| IPO 이후 변동 | -99.90% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 26
HRTX: Appeal Of Patent Ruling Will Shape Future Profitability Outlook
The analyst price target for Heron Therapeutics has been reduced from $4.75 to $3.00, as analysts factor in the recent Cinvanti patent setback, higher perceived risk, and lower projected profitability, despite a higher assumed future P/E multiple. Analyst Commentary Analyst views on Heron Therapeutics have shifted quickly following the Cinvanti patent decision, with several adjustments to ratings and price targets that reflect both legal risk and revenue concentration in this product.
내러티브 업데이트 • Jun 12
HRTX: Patent Appeal Outcome Will Shape Future Pricing Opportunity
Heron Therapeutics' updated analyst price target has moved down from $4 to $2, as analysts factor in the recent court decision on Cinvanti patents, the potential for generic competition, and reduced assumptions for growth, profitability, and fair value, alongside a higher discount rate and P/E multiple. Analyst Commentary Recent street research around Heron Therapeutics reflects a clear reset in expectations after the court ruling on Cinvanti patents.Recent updates
내러티브 업데이트 • Jun 26
HRTX: Appeal Of Patent Ruling Will Shape Future Profitability Outlook
The analyst price target for Heron Therapeutics has been reduced from $4.75 to $3.00, as analysts factor in the recent Cinvanti patent setback, higher perceived risk, and lower projected profitability, despite a higher assumed future P/E multiple. Analyst Commentary Analyst views on Heron Therapeutics have shifted quickly following the Cinvanti patent decision, with several adjustments to ratings and price targets that reflect both legal risk and revenue concentration in this product.내러티브 업데이트 • Jun 12
HRTX: Patent Appeal Outcome Will Shape Future Pricing Opportunity
Heron Therapeutics' updated analyst price target has moved down from $4 to $2, as analysts factor in the recent court decision on Cinvanti patents, the potential for generic competition, and reduced assumptions for growth, profitability, and fair value, alongside a higher discount rate and P/E multiple. Analyst Commentary Recent street research around Heron Therapeutics reflects a clear reset in expectations after the court ruling on Cinvanti patents.
내러티브 업데이트 • May 29
HRTX: Reaffirmed 2026 Guidance And Execution Focus May Support Future Upside
Analysts have trimmed their price target on Heron Therapeutics by $2 to reflect updated views on discount rates, expected revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent commentary on Heron Therapeutics centers on how updated assumptions for discount rates, revenue trajectories, margins and future P/E multiples feed into valuation.내러티브 업데이트 • May 13
HRTX: Revised Profit Outlook And Discount Rate Could Support Future Upside
Analysts have reduced their price target on Heron Therapeutics by $2, citing updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E as the main factors behind the adjustment. Analyst Commentary Recent research points to a more cautious stance on valuation for Heron Therapeutics, with the latest $2 reduction in the price target linked to refreshed assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E levels.Seeking Alpha • Feb 18
Heron: Near The Bottom Of A Trading Range Despite Positives
Summary HRTX has reported preliminary Q4'25 net revenues, with Zynrelef experiencing a breakout quarter. Aponvie sales are also still growing, with the acute care franchise being able to offset declines in the oncology care franchise. HRTX recently dealt with its 2026 convertible notes, although the company does now have debt maturing in 2030 and 2031. Read the full article on Seeking Alpha분석 기사 • Feb 12
Here's Why Heron Therapeutics (NASDAQ:HRTX) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Dec 16
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have had a really impressive month, gaining 27% after a shaky period...분석 기사 • Nov 08
Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported, And Analysts Assigned A US$4.50 Price Target
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) missed earnings with its latest third-quarter results, disappointing...내러티브 업데이트 • Aug 15
Advanced Non-Opioid Therapies Will Transform The Pain Management Market
With both the discount rate and consensus revenue growth forecasts for Heron Therapeutics remaining stable, the consensus analyst price target has consequently held steady at $4.75 per share. What's in the News Reaffirmed Q1 2025 net revenue guidance of $153.0 million to $163.0 million.분석 기사 • May 09
Heron Therapeutics, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Shareholders might have noticed that Heron Therapeutics, Inc. ( NASDAQ:HRTX ) filed its quarterly result this time last...
새로운 내러티브 • Apr 29
ZYNRELEF Label Expansion And VAN Launch Will Broaden Medical Access
Expansion of ZYNRELEF labeling and VAN launch enhance market potential, operational efficiency, and revenue growth.분석 기사 • Apr 18
Lacklustre Performance Is Driving Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 26% Price Drop
The Heron Therapeutics, Inc. ( NASDAQ:HRTX ) share price has softened a substantial 26% over the previous 30 days...Seeking Alpha • Mar 08
Heron Therapeutics: Four Horse Race Of Approved Therapies
Summary Heron Therapeutics' market cap has risen to ~$360 million, trading at ~$2.38, since my last "Hold" rating in November 2024. I will evaluate Heron's investment merits based on its full year and Q4 2024 earnings, reported on February 27, 2025. The analysis includes insights from Heron's earnings press release, conference call, 10-Q, and presentation. Heron has demonstrated a variety of successful outcomes, warranting a reassessment of its investment potential. Read the full article on Seeking Alpha분석 기사 • Mar 01
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry
Despite an already strong run, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have been powering on, with a gain of...분석 기사 • Nov 13
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge
The Heron Therapeutics, Inc. ( NASDAQ:HRTX ) share price has fared very poorly over the last month, falling by a...분석 기사 • Nov 13
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders that were waiting for something to happen have been dealt a blow...분석 기사 • Aug 08
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders that were waiting for something to happen have been dealt a blow...분석 기사 • May 30
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • Apr 16
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Summary HRTX has received approval for its supplemental New Drug Application for Zynrelef, allowing its use in more surgical procedures. The company has partnered with Crosslink Life Sciences to promote Zynrelef, which could further drive sales growth. The availability of a vial access needle form of Zynrelef might not come until late 2024, but offers an additional milestone for Zynrelef's expansion. Read the full article on Seeking Alpha분석 기사 • Mar 15
Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) investors will be delighted, with the company turning in some strong numbers...분석 기사 • Feb 15
Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have continued their recent momentum with a 27% gain in the last month...분석 기사 • Dec 22
Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Despite an already strong run, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have been powering on, with a gain of...주주 수익률
| HRTX | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | -0.3% | 4.0% | -0.7% |
| 1Y | -80.7% | 42.5% | 20.3% |
수익률 대 산업: HRTX은 지난 1년 동안 42.5%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: HRTX은 지난 1년 동안 20.3%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| HRTX volatility | |
|---|---|
| HRTX Average Weekly Movement | 17.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: HRTX의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: HRTX의 주간 변동성은 지난 1년간 12%에서 18%로 증가했습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1983 | 128 | Craig Collard | www.herontx.com |
상업화 단계의 생명공학 회사인 헤론 테라퓨틱스는 의료 서비스를 향상시키는 치료제를 개발 및 상용화하는 데 주력하고 있습니다. 이 회사의 제품 후보들은 단 한 번의 투여로 수일에서 수주에 걸쳐 치료 수준의 다양한 단기 작용 약물을 전달하는 독점적인 약물 전달 기술인 바이오크로노머를 활용합니다. 중등도 구토 유발 화학 요법 또는 안트라사이클린과 사이클로포스파마이드 병용 화학 요법과 관련된 급성 및 지연성 오심과 구토를 예방하기 위한 서방형 주사제인 SUSTOL(그라니세트론)을 제공합니다; 그리고 고도의 구토 유발성 암 화학 요법과 관련된 급성 및 지연성 구역 및 구토와 중간 정도의 구토 유발성 암 화학 요법과 관련된 구역 및 구토를 예방하기 위한 물질 P/뉴로키닌-1 수용체 길항제인 아프레피탄트 정맥 제형인 신반티(CINVANTI)를 개발 중입니다.
Heron Therapeutics, Inc. 기초 지표 요약
| HRTX 기초 통계 | |
|---|---|
| 시가총액 | US$82.13m |
| 순이익 (TTM) | -US$30.94m |
| 매출 (TTM) | US$150.71m |
0.5x
주가매출비율(P/S)-2.6x
주가수익비율(P/E)HRTX는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| HRTX 손익계산서 (TTM) | |
|---|---|
| 매출 | US$150.71m |
| 매출원가 | US$56.06m |
| 총이익 | US$94.65m |
| 기타 비용 | US$125.59m |
| 순이익 | -US$30.94m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.16 |
| 총이익률 | 62.80% |
| 순이익률 | -20.53% |
| 부채/자본 비율 | 1,550.1% |
HRTX의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/07 12:23 |
| 종가 | 2026/07/07 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Heron Therapeutics, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Liisa Bayko | Citizens JMP Securities, LLC |
| Joshua Schimmer | Evercore ISI |